PPMS patients taking Ocrevus are less likely to see progression
Having recently concluded an ORATORIO phase III clinical trial of primary progressive multiple sclerosis (PPMS) patients, Genentech’s Ocrevus (ocrelizumab) increased the number of patients found to have no experienced progression (NEP) when taking the drug...Read more - http://www.ms-uk.org/ppms-patients-taki ... ion-100317
PPMS patients taking Ocrevus are less likely to progress...
PPMS patients taking Ocrevus are less likely to progress...
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2181 Views
-
Last post by NHE
-
- 0 Replies
- 1044 Views
-
Last post by NHE
-
- 0 Replies
- 10370 Views
-
Last post by NHE
-
- 0 Replies
- 2084 Views
-
Last post by Firidion
-
- 1 Replies
- 1359 Views
-
Last post by vesta
-
- 0 Replies
- 2094 Views
-
Last post by frodo
-
- 0 Replies
- 2009 Views
-
Last post by NHE
-
- 0 Replies
- 1517 Views
-
Last post by NHE
-
- 4 Replies
- 2509 Views
-
Last post by JohnC777